Bicycle Therapeutics plc (BCYC)

Etorro trading 970x250
Bicycle Therapeutics plc (BCYC) Logo

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Address: Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT

Bicycle Therapeutics plc News and around…

Latest news about Bicycle Therapeutics plc (BCYC) common stock and company :

Bicycle Therapeutics: Q2 Earnings Insights
04 Aug, 2022 FinancialContent

Bicycle Therapeutics (NASDAQ:BCYC) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's ...

Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
04 Aug, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2022 and provided recent corporate updates.

Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
02 Aug, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting data using tris-Gold complexes to increase the chemical diversity of Bicycles, was published in Bioconjugate Chemistry. The article, titled “Gold-Mediated Multiple Cysteine Arylation for the Construction of Highly Constrained Bicycle Peptides” is available at the publications section of the Bicycle website at this link.

Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
28 Jul, 2022 FinancialContent

Upgrades According to Argus Research, the prior rating for Huntington Bancshares Inc (NASDAQ:HBAN) was changed from Hold ...

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
12 Jul, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT7480, a Bicycle tumor-targeted immune cell agonist® (Bicycle TICA™) targeting Nectin-4 and agonizing CD137 (4-1BB), was published in the Journal of Medicinal Chemistry. The article, titled “Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology” is available at the publications section of the Bicycle website at this link.

Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
12 Jul, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that Genentech, a member of the Roche Group, has exercised its second option to initiate a new program, expanding the exclusive strategic collaboration agreement with Bicycle to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies.

Where Bicycle Therapeutics Stands With Analysts
06 Jul, 2022 FinancialContent

Over the past 3 months, 5 analysts have published their opinion on Bicycle Therapeutics (NASDAQ:BCYC) stock. These analysts are ...

Bicycle Therapeutics (NASDAQ:BCYC) jumps 16% this week, taking three-year gains to 88%
30 Jun, 2022 Yahoo! Finance

Some Bicycle Therapeutics plc ( NASDAQ:BCYC ) shareholders are probably rather concerned to see the share price fall...

12 Health Care Stocks Moving In Friday's Pre-Market Session
24 Jun, 2022 FinancialContent

Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of ...

Peek Under The Hood: BIB Has 61% Upside
17 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $63.77 per unit.

Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
08 Jun, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the expansion portion of the Phase I/II study of BT5528, Bicycle’s second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2.

Stocks That Hit 52-Week Lows On Monday
06 Jun, 2022 FinancialContent

Monday's session saw 84 companies set new 52-week lows. Facts of Interest About Today's 52-Week ...

Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
01 Jun, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 8:00 a.m. ET.

Stocks That Hit 52-Week Lows On Friday
27 May, 2022 FinancialContent

During Friday's session, 59 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week ...

Bicycle Therapeutics's Return On Capital Employed Overview
27 May, 2022 FinancialContent

Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, ...

Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
26 May, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will present a Trials in Progress poster highlighting the Phase I/II clinical trial of BT7480, a novel, fully synthetic Bicycle TICA™ targeting Nectin-4 and agonizing CD137, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL on June 3-7, 2022.

Analyst Ratings for Bicycle Therapeutics
23 May, 2022 FinancialContent

Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
16 May, 2022 Yahoo! Finance

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Expert Ratings for Bicycle Therapeutics
06 May, 2022 FinancialContent

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: Bullish Somewhat ...

Recap: Bicycle Therapeutics Q1 Earnings
05 May, 2022 FinancialContent

Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what ...

Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
05 May, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2022 and provided recent corporate updates.

Analysts Are Downgrading These 10 Pharmaceutical Stocks
20 Apr, 2022 Yahoo! Finance

In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry always remains in focus as investors scramble to find innovative companies working on treatments of diseases. The […]

B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33
13 Apr, 2022 FinancialContent

B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its ...

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
13 Apr, 2022 FinancialContent

Upgrades According to Oppenheimer, the prior rating for Apollo Global Management Inc (NYSE:APO) was changed from Perform to Outperform. ...

Here's Why Bicycle Therapeutics Stock Looks Ill Today
11 Apr, 2022 FinancialContent

Lackluster clinical trial results for its lead candidate are to blame.

12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Apr, 2022 FinancialContent

Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their ...

Bicycle Therapeutics PLC Sponsored ADR (BCYC) Stock Jumps 24.5%: Will It Continue to Soar?
11 Apr, 2022 Yahoo! Finance

Bicycle Therapeutics PLC Sponsored ADR (BCYC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
11 Apr, 2022 FinancialContent

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4. The results were presented in an oral presentation on Sunday, April 10 at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, LA.

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
10 Apr, 2022 FinancialContent

Biotech stocks managed to carve out modest gains for the week endingApril 8, defying the broader market weakness. The defensive ...

Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid?
08 Apr, 2022 FinancialContent

Bicycle Therapeutics said Friday its antiviral drug successfully blocked Covid in rats — and the biotech stock rocketed to a two-month high.

Bicycle Therapeutics plc (BCYC) is a NASDAQ Common Stock listed in , ,

970x250